This product, (R)-Mevalonolactone, CAS No. 19115-49-2, has an application in improving epidermal barrier function and preventing deterioration of dry skin.

According to the paper by Chen et. al., mevalonolactone (MVL in short), is able to:

1. increase the mRNA and protein levels of ABCA12, a critical transporter involved in lipid transport to lamellar granules in keratinocytes.

2. incease the number, size, and fluorescence intensity of Nile red-stained lamellar granules in cultured keratinocytes, indicating increased lipid content in these granules.

3. In a 3D human epidermis model, MVL decreased transepidermal water loss (TEWL) by 27% compared to control, suggesting improved barrier function. MVL also increased free fatty acid content and Nile red-stained lamellar granules in this 3D model.

4. In a human clinical trial, topical application of a milky lotion containing 0.1% MVL for 2 weeks significantly improved TEWL and lipid content on the skin surface compared to placebo, indicating prevention of barrier function deterioration in dry skin during winter.

5. The proposed mechanism is that MVL increases free fatty acid uptake and PPAR β/δ expression in keratinocytes, leading to increased ABCA12 levels and lipid transport to lamellar granules, thereby improving epidermal barrier function.

Reference